Imaging infection with compounds that bind to thymidine kinase
The instant invention provides a method for diagnosing an infection in a subject by administering to the subject a compound suitable for imaging which binds to a thymidine kinase present in the infecting organism, and obtaining an image of the subject to determine the presence and location of the compound, wherein a localization of the compound is indicative that the subject has an infection.
1. A method for diagnosing a bacterial infection in a subject comprising:
administering to the subject a compound suitable for imaging which binds to an endogenous bacterial thymidine kinase present in the infecting bacteria; and
obtaining an image of the subject to determine the presence and location of the compound; wherein a localization of the compound is indicative that the subject has a bacterial infection wherein the compound is a radiolabeled nucleoside.
2. The method of claim 1 , wherein the image of the subject is acquired by a method selected from the group consisting of planar gamma imaging, single photon emission computed tomography (SPECT) and positron emission tomography (PET).
3. The method of claim 1 , wherein the nucleoside analog is labeled with radioactive fluorine or iodine.
4. The method of claim 3 , wherein the compound is selected from the group consisting of 2′-fluoro-2′deoxy-1-beta-D-arabinofuranosyl-5-iodo-uracil ([125I]-FIAU), 2′-fluoro-2′deoxy-1-beta-D-arabinofuranosyl-5-iodo-uracil ([124I]-FIAU), 9-(4-18F-fluoro-3-[hydroxymethyl]butyl)guanine ([18F]-FHBG), (18)F-1-(2′-deoxy-2′-fluoro-beta-d-arabinofuranosyl)thymine ([18F]-FMAU), 18F-2′-fluoro-2′deoxy-1beta-D-arabinofuranosyl-5-ethyl-uracil ([18F]-FEAU) and 1-(2′-deoxy-2′-fluoro-beta-D-arabinofuranosyl)-5-[18F] iodouracil ([18F]-FIAU).
5. The method of claim 1 , wherein the nucleoside analog emits gamma particles.
6. The method of claim 1 , wherein the nucleoside analog is fluorescent.
7. The method of claim 1 , wherein the bacterial infection is caused by bacteria from a genus selected from the group consisting of Escherichia, Bacillus, Chromobacterium, Clostridium, Enteroccus, Haemophilus, Listeria, Mycoplasma, Pasteruella, Salmonella, Staphylococcus, Streptococcus, Streptomyces, Vibrio , and Yersinia.
8. A method for imaging a bacterial infection in a subject comprising:
administering to the subject a compound suitable for imaging which binds to an endogenous bacterial thymidine kinase present in the infecting bacteria; and
obtaining an image of the subject;
thereby obtaining an image of the bacterial infection in a subject wherein the compound is a radiolabeled nucleoside.
9. The method of claim 8 , wherein the image of the subject is acquired by a method selected from the group consisting of planar gamma imaging, single photon emission computed tomography (SPECT) and positron emission tomography (PET).
10. The method of claim 8 , wherein the compound is selected from the group consisting of 2′-fluoro-2′deoxy-1-beta-D-arabinofuranosyl-5-iodo-uracil ([125I]-FIAU), 2′-fluoro-2′deoxy-1-beta-D-arabinofuranosyl-5-iodo-uracil ([124I]-FIAU), 9-(4-18F-fluoro-3-[hydroxymethyl]butyl)guanine ([18F]-FHBG), (18)F-1-(2′-deoxy-2′-fluoro-beta-d-arabinofuranosyl)thymine ([18F]-FMAU), 18F-2′-fluoro-2′deoxy-1beta-D-arabinofuranosyl-5-ethyl-uracil ([18F]-FEAU) and 1-(2′-deoxy-2′-fluoro-beta-D-arabinofuranosyl)-5-[18F] iodouracil ([18F]-FIAU).
11. The method of claim 8 , wherein the nucleoside analog emits gamma particles.
12. The method of claim 8 , wherein the nucleoside analog is fluorescent.
13. The method of claim 8 , wherein the compound suitable for imaging is an antibacterial compound.
14. The method of claim 8 , where the method allows for the differentiation of bacterial infection and inflammation.
15. The method of claim 14 , wherein the compound is an antibacterial, antiviral, or antifungal compound.
16. A method for imaging bacterial-based anticancer therapy comprising:
administering to a subject a compound suitable for imaging which binds to an endogenous bacterial thymidine kinase present in a therapeutic bacteria; and
imaging the subject to determine the presence and location of the compound;
thereby imaging a bacterial-based anticancer therapy wherein the compound is a radiolabeled nucleoside.
17. The method of claim 16 , wherein the image of the subject is acquired by a method selected from the group consisting of planar gamma imaging, single photon emission computed tomography (SPECT) and positron emission tomography (PET).
18. The method of claim 16 , wherein the nucleoside analog is labeled with radioactive fluorine or iodine.
19. The method of claim 18 , wherein the compound is selected from the group consisting of 2′-fluoro-2′deoxy-1-beta-D-arabinofuranosyl-5-iodo-uracil ([125I]-FIAU), 2′-fluoro-2′deoxy-1-beta-D-arabinofuranosyl-5-iodo-uracil ([124I]-FIAU), 9-(4-18F-fluoro-3-[hydroxymethyl]butyl)guanine ([18F]-FHBG), (18)F-1-(2′-deoxy-2′-fluoro-beta-d-arabinofuranosyl)thymine ([18F]-FMAU), 18F-2′-fluoro-2′deoxy-1beta-D-arabinofuranosyl-5-ethyl-uracil ([18F]-FEAU) and 1-(2′-deoxy-2′-fluoro-beta-D-arabinofuranosyl)-5-[18F] iodouracil ([18F]-FIAU).
20. The method of claim 16 , wherein the nucleoside analog emits gamma particles.
21. The method of claim 16 , wherein the nucleoside analog is fluorescent.